This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ADAP Adaptimmune Therapeutics (ADAP) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Adaptimmune Therapeutics Stock (NASDAQ:ADAP) Get ADAP alerts:Sign Up Key Stats Today's Range$0.05▼$0.0750-Day Range$0.05▼$0.2252-Week Range$0.04▼$0.36Volume49.26 million shsAverage Volume57.14 million shsMarket Capitalization$15.35 millionP/E RatioN/ADividend YieldN/APrice Target$0.50Consensus RatingReduce Company Overview Adaptimmune Therapeutics plc is a clinical-stage biotechnology company focused on the development of novel T-cell therapies for the treatment of solid tumors. The company’s proprietary technology platform, known as SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cells, uses affinity-enhanced T-cell receptors (TCRs) to target cancer-associated antigens with precision. Adaptimmune’s research and development efforts are centered on engineering patient-derived T cells to recognize and eliminate tumor cells while sparing healthy tissues. Since its founding in 2008 as a spin-out from Oxford University, Adaptimmune has advanced multiple product candidates into clinical trials. Lead programs include ADP-A2M4, targeting the cancer testis antigen MAGE-A4, and ADP-A2AFP, directed against alpha-fetoprotein in liver cancer. The company also maintains preclinical discovery efforts against other tumor-associated antigens, aiming to expand its pipeline across a range of solid tumor indications such as ovarian, head and neck, and lung cancers. Adaptimmune operates research and development facilities in Oxford, U.K., and a clinical and manufacturing center in Philadelphia, Pennsylvania. The company conducts multicenter clinical trials primarily in the United States and Europe, collaborating with academic institutions and biopharmaceutical partners to facilitate patient access and advance its programs through late-stage development. Governed by a management team with deep expertise in oncology and cell therapy, Adaptimmune is led by Chief Executive Officer James Noble, who joined the company in 2021. Adaptimmune Therapeutics is publicly traded on the Nasdaq Global Market under the ticker symbol ADAP and continues to pursue strategic collaborations and potential regulatory filings as it works to bring its engineered T-cell therapies to patients with unmet medical needs.AI Generated. May Contain Errors. Read More Adaptimmune Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks18th Percentile Overall ScoreADAP MarketRank™: Adaptimmune Therapeutics scored higher than 18% of companies evaluated by MarketBeat, and ranked 811th out of 860 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.9 / 5Analyst RatingReduce Consensus RatingAdaptimmune Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.75, and is based on no strong buy ratings, no buy ratings, 3 hold ratings, and 1 sell rating.Upside PotentialAdaptimmune Therapeutics has a consensus price target of $0.50, representing about 763.6% upside from its current price of $0.06.Amount of Analyst CoverageAdaptimmune Therapeutics has received no research coverage in the past 90 days.Read more about Adaptimmune Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Adaptimmune Therapeutics are expected to decrease in the coming year, from ($0.14) to ($0.48) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Adaptimmune Therapeutics is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Adaptimmune Therapeutics is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAdaptimmune Therapeutics has a P/B Ratio of 1.16. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for ADAP. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAdaptimmune Therapeutics does not currently pay a dividend.Dividend GrowthAdaptimmune Therapeutics does not have a long track record of dividend growth. News and Social Media0.0 / 5News SentimentN/A Search InterestOnly 1 people have searched for ADAP on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Adaptimmune Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders12.44% of the stock of Adaptimmune Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions31.37% of the stock of Adaptimmune Therapeutics is held by institutions.Read more about Adaptimmune Therapeutics' insider trading history. Receive ADAP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adaptimmune Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ADAP Stock News HeadlinesSixteen new option listings and one option delisting on October 28thOctober 28, 2025 | msn.comAdaptimmune delists from Nasdaq, shifts focus after asset sale to US WorldMedsOctober 28, 2025 | bizjournals.comBefore you buy SpaceX shares, consider this alternative approachSpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceeding $1.75 trillion - potentially the largest IPO in history. But one expert says buying shares directly may not be the smartest move. There is a lesser-known way to tap into this windfall that most investors haven't considered.May 19 at 1:00 AM | Weiss Ratings (Ad)Evaxion Biotech appoints Tayton-Martin as new CEOOctober 27, 2025 | msn.comLiposarcoma Market Set to Grow at a Steady CAGR by 2034 Amid Increasing Clinical Research Activities | DelveInsightOctober 21, 2025 | finance.yahoo.comAdaptimmune stock plunges after announcing Nasdaq delisting plansOctober 20, 2025 | au.investing.comAdaptimmune Therapeutics PLC: Adaptimmune Announces Delisting from NasdaqOctober 20, 2025 | finanznachrichten.deWhy Is Adaptimmune Therapeutics Stock (ADAP) Rising Today?October 10, 2025 | msn.comSee More Headlines ADAP Stock Analysis - Frequently Asked Questions How were Adaptimmune Therapeutics' earnings last quarter? Adaptimmune Therapeutics PLC (NASDAQ:ADAP) issued its earnings results on Wednesday, August, 13th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.15) by $0.04. The biotechnology company earned $13.68 million during the quarter, compared to analyst estimates of $11.04 million. Adaptimmune Therapeutics had a negative trailing twelve-month return on equity of 163.73% and a negative net margin of 260.82%. When did Adaptimmune Therapeutics IPO? Adaptimmune Therapeutics (ADAP) raised $150 million in an initial public offering (IPO) on Wednesday, May 6th 2015. The company issued 9,400,000 shares at a price of $15.00-$17.00 per share. BofA Merrill Lynch, Cowen and Company and Leerink Partners acted as the underwriters for the IPO and Guggenheim Securities was co-manager. What other stocks do shareholders of Adaptimmune Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Adaptimmune Therapeutics investors own include Voyager Therapeutics (VYGR), Waste Connections (WCN), DiamondRock Hospitality (DRH), American Water Works (AWK), The RMR Group (RMR), AUO (AUOTY) and iShares Micro-Cap ETF (IWC). Company Calendar Last Earnings8/13/2025Today5/19/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ADAP CIK1621227 Webwww.adaptimmune.com Phone441235430000Fax44-12-3543-0001Employees490Year Founded2008Price Target and Rating Average Price Target for Adaptimmune Therapeutics$0.50 High Price Target$0.50 Low Price Target$0.50 Potential Upside/Downside+763.6%Consensus RatingReduce Rating Score (0-4)1.75 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($0.65) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$70.81 million Net Margins-260.82% Pretax Margin-255.12% Return on Equity-163.73% Return on Assets-75.83% Debt Debt-to-Equity RatioN/A Current Ratio1.52 Quick Ratio1.29 Sales & Book Value Annual Sales$178.03 million Price / Sales0.09 Cash FlowN/A Price / Cash FlowN/A Book Value$0.05 per share Price / Book1.16Miscellaneous Outstanding Shares265,050,000Free Float232,080,000Market Cap$15.35 million OptionableOptionable Beta2.49 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:ADAP) was last updated on 5/19/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adaptimmune Therapeutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Adaptimmune Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
